Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

clinical trial

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00720512

P6099clinical trial phasephase III clinical trialQ42824827
P17countryItalyQ38
P582end time2013-02-01
P921main subjectrectum adenocarcinomaQ18554959
P4135maximum age75
P2899minimum age18
P1132number of participants184
P4844research interventionfluorouracilQ238512
irinotecanQ412197
calcium oxalateQ412399
bevacizumabQ413299
leucovorin calciumQ27077063
P6153research siteAzienda Ospedaliera Universitaria SeneseQ17622143
P1813short nameBEBYP
P580start time2008-06-01
P8363study typeinterventional studyQ78089383
P1476titleAN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.